• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

尿激酶型纤溶酶原激活剂在各种人甲状腺组织中的表达。

Expression of urokinase-type plasminogen-activator in various human thyroid tissues.

机构信息

OSAKA UNIV,SCH MED,DIV SURG PATHOL,OSAKA 565,JAPAN.

出版信息

Oncol Rep. 1995 Jul;2(4):525-8. doi: 10.3892/or.2.4.525.

DOI:10.3892/or.2.4.525
PMID:21597769
Abstract

High levels of urokinase-type plasminogen activator (u-PA) have been detected in malignant tissues of various organs and these are thought to be related to the local invasion and distant metastasis of carcinomas. In the present study, the expression of u-PA was immunohistochemically investigated in various thyroid tissues by using formaline-fixed, paraffin-embedded tissue sections. Normal thyroid expressed hardly any u-PA. In some hyperplasias, weak u-PA immunoreactivity was observed in small follicles and in clusters of follicular cells in the process of regenerating hyperplastic follicles. However very intense u-PA staining was observed in all cases of chronic thyroiditis in the small follicules surrounded by numerous lymphocytes. This indicates that u-PA must be strongly implicated in this disease together with various cytokines. As much as 90% of the carcinomas in our study expressed u-PA in the cytoplasm of carcinoma cells and the expression in carcinomas was much more extensive than that in benign adenomas. Although this carcinoma is known to have a generally good prognosis, our findings suggest that u-PA reflects malignancy in tumoral growth of the thyroid and modulates this growth from its early stage.

摘要

在各种器官的恶性组织中检测到高水平的尿激酶型纤溶酶原激活物 (u-PA),这些被认为与癌的局部浸润和远处转移有关。在本研究中,通过使用福尔马林固定、石蜡包埋的组织切片,用免疫组织化学方法研究了各种甲状腺组织中的 u-PA 表达。正常甲状腺几乎不表达 u-PA。在一些增生中,在再生增生滤泡的过程中小滤泡和滤泡细胞簇中观察到弱的 u-PA 免疫反应性。然而,在所有慢性甲状腺炎的小滤泡中都观察到非常强烈的 u-PA 染色,这些小滤泡周围有大量淋巴细胞。这表明 u-PA 必须与各种细胞因子一起强烈参与这种疾病。我们研究中的 90%的癌在癌细胞的细胞质中表达 u-PA,并且在癌中的表达比在良性腺瘤中的表达更为广泛。尽管这种癌通常预后良好,但我们的研究结果表明,u-PA 反映了甲状腺肿瘤生长中的恶性程度,并从早期阶段调节这种生长。

相似文献

1
Expression of urokinase-type plasminogen-activator in various human thyroid tissues.尿激酶型纤溶酶原激活剂在各种人甲状腺组织中的表达。
Oncol Rep. 1995 Jul;2(4):525-8. doi: 10.3892/or.2.4.525.
2
Immunohistochemical localization of urokinase-type plasminogen activator, type-1 plasminogen-activator inhibitor, urokinase receptor and alpha(2)-macroglobulin receptor in human breast carcinomas.尿激酶型纤溶酶原激活剂、1型纤溶酶原激活剂抑制剂、尿激酶受体及α₂-巨球蛋白受体在人乳腺癌中的免疫组织化学定位
Int J Cancer. 1996 May 16;66(4):441-52. doi: 10.1002/(SICI)1097-0215(19960516)66:4<441::AID-IJC6>3.0.CO;2-W.
3
Detection of mRNAs for urokinase-type plasminogen activator, its receptor, and type 1 inhibitor in giant cell tumors of bone with in situ hybridization.原位杂交检测骨巨细胞瘤中尿激酶型纤溶酶原激活剂、其受体及1型抑制剂的mRNA
Am J Pathol. 1995 Dec;147(6):1559-66.
4
Immunolocalization of urokinase-type plasminogen activator in adenomas and carcinomas of the colorectum.
Histopathology. 1991 Sep;19(3):231-7. doi: 10.1111/j.1365-2559.1991.tb00027.x.
5
Increased urokinase receptor levels in human gastrointestinal neoplasia and related liver metastases.
Invasion Metastasis. 1993;13(6):277-88.
6
Expression of urokinase-type plasminogen activator (u-PA), u-PA receptor, and tissue-type PA messenger RNAs in human hepatocellular carcinoma.尿激酶型纤溶酶原激活剂(u-PA)、u-PA受体及组织型纤溶酶原激活剂信使核糖核酸在人肝细胞癌中的表达
Cancer Res. 1998 May 15;58(10):2234-9.
7
Localization of urokinase-type plasminogen activator, plasminogen activator inhibitor-1, 2 and plasminogen in colon cancer.尿激酶型纤溶酶原激活物、纤溶酶原激活物抑制剂-1、2及纤溶酶原在结肠癌中的定位
Jpn J Cancer Res. 1995 Jan;86(1):48-56. doi: 10.1111/j.1349-7006.1995.tb02987.x.
8
Immunohistochemical demonstration of epidermal growth-factor receptors in normal, benign and malignant thyroid tissues.
Int J Oncol. 1992 Aug;1(3):331-5. doi: 10.3892/ijo.1.3.331.
9
Expression of urokinase plasminogen activator, its receptor and type-1 inhibitor in malignant and benign prostate tissue.尿激酶型纤溶酶原激活剂、其受体及1型抑制剂在前列腺良恶性组织中的表达
Int J Cancer. 2005 Mar 1;113(6):870-80. doi: 10.1002/ijc.20665.
10
Clinical relevance of urokinase plasminogen activator, its receptor, and its inhibitor in patients with renal cell carcinoma.尿激酶型纤溶酶原激活剂及其受体和抑制剂在肾细胞癌患者中的临床相关性。
Cancer. 1996 Aug 1;78(3):487-92. doi: 10.1002/(SICI)1097-0142(19960801)78:3<487::AID-CNCR16>3.0.CO;2-V.

引用本文的文献

1
Urokinase-type plasminogen activator and its inhibitor in thyroid neoplasms: a cytosol study.尿激酶型纤溶酶原激活剂及其抑制剂在甲状腺肿瘤中的研究:一项胞质溶胶研究
Wien Klin Wochenschr. 2006 Oct;118(19-20):601-9. doi: 10.1007/s00508-006-0703-1.
2
Expression and localization of urokinase-type plasminogen activator in human spinal column tumors.尿激酶型纤溶酶原激活剂在人脊柱肿瘤中的表达及定位
Clin Exp Metastasis. 1998 Nov;16(8):713-9. doi: 10.1023/a:1006528711499.